NCT03375320: Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 3
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older(Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have progressed on at least 1 prior systemic therapy that included everolimus
Exclusions: Patients with prior treatment of cabozantinib; Patients with known cavitary lung lesions or untreated unstable brain metastases- see trial for details

Comments are closed.

Up ↑